A Phase 2 interventional study of CYT003-QbG10 and Placebo in Rhinoconjunctivitis and Allergies, sponsored by Cytos Biotechnology AG. Completed at 8 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-11-15.
Sponsored by Cytos Biotechnology AG · Phase 2, Interventional, and Treatment
The purpose of the study is to test whether vaccinations with CYT003-QbG10 can improve allergy symptoms in patients with house dust mite allergy. The active treatment will be compared against placebo.
47 studies on the registry are indexed under Dust Mite Allergy; 6 are open to participants now.
This study's planned enrollment of 300 is above the median of 66 across 36 interventional studies indexed under Dust Mite Allergy.
Browse Dust Mite Allergy studies →Cytos Biotechnology AG is the lead sponsor of 18 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: CYT003-QbG10
Drug: CYT003-QbG10
Drug: Placebo
subcutaneous injection
subcutaneous injection
Rhinoconjunctivitis symptom and medication scores
Time frame: Pre- / Post-Treatment
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cytos Biotechnology AG